# MOVIPREP® Versus NaP Pivotal Phase III Study

> **NCT00322062** · PHASE3 · COMPLETED · sponsor: **Norgine** · enrollment: 340 (actual)

## Conditions studied

- Colonoscopy

## Interventions

- **DRUG:** macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
- **DRUG:** Sodium Phosphate Solution

## Key facts

- **NCT ID:** NCT00322062
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2003-03
- **Target enrollment:** 340 (ACTUAL)
- **Last updated:** 2008-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322062, "MOVIPREP® Versus NaP Pivotal Phase III Study". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00322062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*